66 completed, 17 unknown, 16 terminated, 13 recruiting. 139 Phase 2, 13 Phase 1, 3 Phase 3.
Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer Abemaciclib, Tersolisib, Letrozole - Breast Neoplasms | Phase 2 | Not yet recruiting | Eli Lilly and Company | 120 | 2026-12-01 | 2026-11-13 |
| KC1086 in Combination With Fulvestrant for HR-Positive, HER2-Negative Advanced Breast Cancer KC1086, Fulvestrant, Everolimus (10 mg QD) - HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer | Phase 2 | Not yet recruiting | Beijing Konruns Pharmaceutical Co., Ltd. | 168 | 2026-11-01 | 2026-11-16 |
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE) elacestrant and exemestane - Breast Cancer | Phase 2 | Recruiting | European Institute of Oncology | 26 | 2026-05-11 | 2026-05-14 |
| Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Diseases, Breast Neoplasms | Phase 2 | Recruiting | Fujian Cancer Hospital | 2000 | 2026-01-21 | 2026-05-12 |
| An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer Trastuzumab and Pertuzumab Combination with Palbociclib and Exemestane - Breast Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 90 | 2025-12-20 | 2025-12-23 |
| Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. Tamoxifen 10 MG, Exemestane 25 MG - Breast Cancer | Phase 2 | Recruiting | Andrea DeCensi | 140 | 2025-10-01 | 2025-11-18 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 288 | 2025-09-10 | 2025-09-18 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) Belzutifan, Fulvestrant, Everolimus - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 120 | 2024-11-27 | 2026-08-28 |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer Abemaciclib, Anastrozole, Biospecimen Collection - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 60 | 2024-07-22 | 2026-09-24 |
| Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy Letrozole, Anastrozole, Exemestane - HR+/HER2- Advanced/Metastatic Breast Cancer | Phase 2 | Active not recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 78 | 2024-02-29 | 2025-05-04 |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 400 | 2024-02-17 | 2026-10-26 |
| Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors Biospecimen Collection, Chest Radiography, Computed Tomography - Adult Ovarian Granulosa Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2024-02-08 | 2026-11-03 |
| First-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast Cancer Ribociclib - Advanced Breast Cancer | Phase 2 | Completed | The First Affiliated Hospital with Nanjing Medical University | 74 | 2024-01-09 | 2026-08-05 |
Showing 20 of 139. Sign in to see all of them.
Breast Neoplasms (112) · Neoplasm Metastasis (8) · Breast Diseases (4) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Neoplasms (2) · Prostatic Neoplasms (2) · Breast Carcinoma In Situ (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Ductal (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Carcinoma, Non-Small-Cell Lung (1) · Endometrial Hyperplasia (1) · Endometrial Stromal Tumors (1) · Granulosa cell tumor of the ovary (1)
Pfizer (9) · Dana-Farber Cancer Institute (5) · Novartis Pharmaceuticals (5) · Merck Sharp & Dohme LLC (4) · Eli Lilly and Company (3) · National Cancer Institute (NCI) (3) · Chinese Academy of Medical Sciences (2) · City of Hope Medical Center (2) · Emory University (2) · Fujian Cancer Hospital (2) · Georgetown University (2) · Mayo Clinic (2) · NYU Langone Health (2) · Ohio State University Comprehensive Cancer Center (2) · Spanish Breast Cancer Research Group (2)
United States (76) · China (20) · Spain (19) · United Kingdom (18) · Belgium (15) · France (14) · Canada (13) · Italy (13) · Germany (9) · Brazil (8) · South Korea (8) · Argentina (7) · Japan (7) · Australia (6) · Ireland (6)
Erica Mayer, MD, MPH (2) · Hannah Linden (2) · Jonas Bergh, Professor (2) · Oana Danciu, MD (2) · Adrian L. Harris, MD (1) · Adrienne C Waks, MD (1) · Alessandro Morabito, M.D. (1) · Andrea Gombos, MD (1) · Andrea U De Censi, MD (1)
PMID 21717449, PMID 22444722, PMID 22674146, PMID 23053638, PMID 23650416, PMID 24498853, PMID 24674873, PMID 25101563, PMID 26504153, PMID 26758879, PMID 26786263, PMID 27903675, PMID 28314691, PMID 28324268, PMID 28681171, PMID 29124456, PMID 29566104, PMID 29608913, PMID 29862411, PMID 29893790, PMID 29899867, PMID 31250880, PMID 31434793, PMID 31668850, PMID 32043762, PMID 32660609, PMID 33451345, PMID 33761970, PMID 33820779, PMID 34667023, PMID 35223459, PMID 35405087, PMID 36398439, PMID 36410913, PMID 36905771, PMID 36951827, PMID 37166817, PMID 37294342, PMID 37308971, PMID 37348019, PMID 37460683, PMID 37690320, PMID 38123789, PMID 38904918, PMID 39028923, PMID 39110531, PMID 39384801, PMID 39730000, PMID 39978378, PMID 41697438
2014 (3), 2017 (3), 2016 (2), 2023 (2), 2009 (1), 2018 (1), 2019 (1), N01CN00033 (1), N01CN00034 (1), P30CA014520 (1), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), R21CA277311 (1)